Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + nab-paclitaxel + panitumumab
- Development stage
- Unknown
- Lead developer
- Johnson Matthey
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of carboplatin (a platinum-based chemotherapy agent), nab-paclitaxel (Abraxane, an albumin-bound form of paclitaxel), and panitumumab (Vectibix, a fully human monoclonal antibody targeting EGFR). This regimen combines conventional chemotherapy with targeted therapy to treat various cancers, particularly studied in HER2-negative inflammatory breast cancer. Nab-paclitaxel utilizes albumin-bound nanoparticles to enhance tumor drug delivery through receptor-mediated transport, while panitumumab blocks EGFR signaling to inhibit tumor growth and promote apoptosis.
02
Targets
Beyond the preview
Go deeper on carboplatin + nab-paclitaxel + panitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + nab-paclitaxel + panitumumab.